Endometrial Hyperplasia Risk in Relation to Recent Use of Oral Contraceptives and Hormone Therapy
| Autor: | Noel S. Weiss, Susan D. Reed, Lynda F. Voigt, Katherine M. Newton, Meira Epplein, Victoria L. Holt |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
medicine.medical_specialty Epidemiology medicine.medical_treatment Population Risk Assessment Article medicine Humans education Reproductive History Progesterone Aged Gynecology education.field_of_study Hysterectomy business.industry Endometrial cancer Estrogen Replacement Therapy Smoking Case-control study Estrogens Hormone replacement therapy (menopause) Odds ratio Middle Aged medicine.disease Endometrial hyperplasia Socioeconomic Factors Endometrial Hyperplasia Female Hormone therapy business Contraceptives Oral |
| Zdroj: | Annals of Epidemiology. 19:1-7 |
| ISSN: | 1047-2797 |
| DOI: | 10.1016/j.annepidem.2008.08.099 |
| Popis: | Purpose We sought to examine the relationship between recent use of oral contraceptives and hormone therapy and endometrial hyperplasia (EH) risk. Methods Cases comprised women diagnosed with complex EH ( n = 289) or atypical EH ( n = 173) between 1985 and 2003. One age-matched control was selected for each case; excluded were women with a prior hysterectomy or diagnosis of EH or endometrial cancer. Hormone use in the 6 months prior to the date of the case's first symptoms was ascertained using a pharmacy database and medical records. Odds ratios (OR) and 95% confidence intervals (CI) were calculated. Results Three (1.1%) cases had used oral contraceptives, compared to 16 (6.0%) controls (OR = 0.2, 95% CI: 0.0–0.6). Fifty-one (16.8%) cases had taken estrogen-only hormone therapy, in contrast to two (0.7%) controls (OR = 37.6, 95% CI: 8.8–160.0). The risk of EH among estrogen plus progestin hormone users did not differ from that of non-users (OR = 0.7, 95% CI: 0.4–1.1). Conclusions This study suggests that previous findings of the association of estrogen-only hormone therapy with increased risk of EH and the lack of an association between estrogen plus progestin hormone therapy and EH risk are likely to apply to both complex EH and atypical EH. Further examination of the association between oral contraceptives and EH, with greater numbers of OC users, is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect